A&M Perspectives: How asset light pharmaceutical companies can augment value creation in a disrupted market environment
Over the past two decades, originator pharmaceutical businesses have increasingly disposed of late-stage drug portfolios to third parties. This has spurred the growth of asset-light pharmaceutical companies with radically different operating models. Operating through networks of Contract Development and Manufacturing Organisations (CDMOs), these businesses avoid major capital expenditure, have greater flexibility, and can therefore focus on critical capabilities such as supply chain excellence, market authorisation and technical transfers.
While there are advantages, asset-light models are complex. Many different partners are involved, comprising of specialised CDMOs, distribution partners and a mix of in-house sales and country distributors. This leads to challenges related to demand planning, inventory control and cost control.
At the same time, asset-light pharma businesses are having to respond to global challenges including rising inflation, supply chain disruptions, Covid-19 outbreaks and growing geopolitical tensions.
Based on our experiences of delivering change for a range of asset-light pharmaceutical companies across Europe, we recommend five levers of value creation.
Five value levers for asset-light pharmaceutical businesses
- CDMO rationalisation and technical transfer excellence
- S&OP/ IBP upgrades
- Inventory and working capital optimisation
- Logistics simplification
- Digital tools deployment (commercial focus)
Download
Related Insights
Shocks to global supply chains are increasing in frequency and severity. Russia’s invasion of Ukraine, new Covid outbreaks in China and rising interest rates in the US are occurring at once with ramifications for global trade. What steps can companies take to improve supply chain resilience.
What’s Your Moonshot? Podcast Series - Episode Briefs
May 6, 2026
In our What’s Your Moonshot? Podcast Series, we seek to uncover big problems in Healthcare and talk to the leaders that are working to solve them.
CareQuest Institute Advancing Access and Affordability in Veterans' Oral Health
May 6, 2026
What if access to oral healthcare was a given—not a barrier—for every veteran? Wade Rakes, Chief Executive Officer of CareQuest Institute for Oral Health joins A&M Healthcare Industry Group's Ken Barrette and David Shulkin, M.D. to share his vision for advancing access, improving affordability, and driving meaningful change in veterans’ oral health.
The Most Undervalued Asset in Health Systems Isn’t a Building — It’s the Physician Enterprise
April 30, 2026
Health systems often look to buildings or rates for growth, but the strongest lever is frequently overlooked. This perspective reframes the physician enterprise as a scalable growth platform, and shows how leaders can unlock margin, resilience, and long-term value.
Access Reimagined: Meeting Evolving Workforce Expectations While Expanding Patient Reach
April 23, 2026
Redesign the system. Realign incentives. Reimagine access. Patrick J. Byrne, M.D., Chief of Cleveland Clinic's Integrated Surgical, and Lisa Ishii, M.D., M.H.S, SVP of Operations for Johns Hopkins Health System join A&M Healthcare Industry Group's Brian Giessler to share their vision for redesigning healthcare to deliver the right care at the right time.
